Literature DB >> 15210114

Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia.

Koh Nakayama1, Ian J Frew, Mette Hagensen, Marianne Skals, Hasem Habelhah, Anindita Bhoumik, Takayuki Kadoya, Hediye Erdjument-Bromage, Paul Tempst, Peter B Frappell, David D Bowtell, Ze'ev Ronai.   

Abstract

Hypoxia-inducible factor-1alpha (HIF1alpha) is a central regulator of the cellular response to hypoxia. Prolyl-hydroxylation of HIF1alpha by PHD enzymes is prerequisite for HIF1alpha degradation. Here, we demonstrate that the abundance of PHD1 and PHD3 are regulated via their targeting for proteasome-dependent degradation by the E3 ubiquitin ligases Siah1a/2, under hypoxia conditions. Siah2 null fibroblasts exhibit prolonged PHD3 half-life, resulting in lower levels of HIF1alpha expression during hypoxia. Significantly, hypoxia-induced HIF1alpha expression was completely inhibited in Siah1a/2 null cells, yet could be rescued upon inhibition of PHD3 by RNAi. Siah2 targeting of PHD3 for degradation increases upon exposure to even mild hypoxic conditions, which coincides with increased Siah2 transcription. Siah2 null mice subjected to hypoxia displayed an impaired hyperpneic respiratory response and reduced levels of hemoglobin. Thus, the control of PHD1/3 by Siah1a/2 constitutes another level of complexity in the regulation of HIF1alpha during hypoxia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210114     DOI: 10.1016/j.cell.2004.06.001

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  169 in total

1.  The ubiquitin ligase Siah2 regulates PPARγ activity in adipocytes.

Authors:  Gail Kilroy; Heather Kirk-Ballard; Lauren E Carter; Z Elizabeth Floyd
Journal:  Endocrinology       Date:  2012-01-31       Impact factor: 4.736

Review 2.  HECT and RING finger families of E3 ubiquitin ligases at a glance.

Authors:  Meredith B Metzger; Ventzislava A Hristova; Allan M Weissman
Journal:  J Cell Sci       Date:  2012-02-01       Impact factor: 5.285

Review 3.  Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease.

Authors:  Monte S Willis; W H Davin Townley-Tilson; Eunice Y Kang; Jonathon W Homeister; Cam Patterson
Journal:  Circ Res       Date:  2010-02-19       Impact factor: 17.367

4.  Ubiquitin ligase Siah2 regulates RevErbα degradation and the mammalian circadian clock.

Authors:  Jason P DeBruyne; Julie E Baggs; Trey K Sato; John B Hogenesch
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-21       Impact factor: 11.205

Review 5.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

Review 6.  New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.

Authors:  Giada Zurlo; Jianping Guo; Mamoru Takada; Wenyi Wei; Qing Zhang
Journal:  Biochim Biophys Acta       Date:  2016-09-20

Review 7.  Ubiquitous points of control over regulatory T cells.

Authors:  Fan Pan; Joseph Barbi
Journal:  J Mol Med (Berl)       Date:  2014-04-29       Impact factor: 4.599

8.  SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia.

Authors:  Jinke Cheng; Xunlei Kang; Sui Zhang; Edward T H Yeh
Journal:  Cell       Date:  2007-11-02       Impact factor: 41.582

9.  Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6).

Authors:  Michaeline L Hebron; Irina Lonskaya; Kaydee Sharpe; Puwakdandawe P K Weerasinghe; Norah K Algarzae; Ashot R Shekoyan; Charbel E-H Moussa
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

10.  Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.

Authors:  Olga Aprelikova; Silvia Pandolfi; Sean Tackett; Mark Ferreira; Konstantin Salnikow; Yvona Ward; John I Risinger; J Carl Barrett; John Niederhuber
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.